China’s surging private health market
August 26 2016 by Nick Ferguson
-
China Re’s overseas P&C business posts robust growth, says AM Best affirming its rating
- November 18
The rating agency noted Chaucer continues to be the major driver of overseas non-life reinsurance revenue.
-
China’s ZhongAn’s operating performance is subject to investment volatility, business risk: AM Best
- November 11
The rating agency affirms financial strength rating of A- (excellent) and long-term issuer credit rating of “a-” (excellent) to the carrier with a stable outlook.
-
Sinosure limits trade credit insurance for exports to Russia: report
- November 8
The Chinese state-owned carrier has reportedly started refusing to insure supplies against the risk of non-payment to Russia fearing payment disruptions and secondary sanctions.
-
Xiaomi joins BNP Paribas, Volkswagen to enter Chinese non-life market
- November 6
The country’s regulator has approved Beijing BNP Paribas Tianxing Property & Casualty Insurance as three-way JV between the smartphone maker's financial services arm, the French banking group and the carmaker's local lending arm.
-
BHSI | Managing non-Asian exposure in long-tail lines
While US-exposed business can look attractive to Asian carriers, managing the volatility around the long-term results and the ability to model those losses are crucial, say BHSI’s Marc Breuil and Marcus Portbury.
-
Sedgwick | To Handle CAT Claims Well, Multi-Step Preparation is Key
When it comes to risk, it’s not a matter of “if” it’s a matter of “when” an event will occur.
-
HSBC Asset Management | Is it time to relook at Asian currency bonds?
With diversification and performance high on investors’ agendas, it seems a good time for global portfolios to revive allocations in Asian local currency bonds – including Hong Kong dollar (HKD) bonds.
-
PineBridge Investments | Why Asian insurers are exploring private credit and CLOs
The recent rollout of risk-based capital regimes across Asia calls for a closer alignment between insurers’ assets and liabilities. We explore potential ways to maintain a healthy investment yield and robust returns on regulatory capital.
